{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:16:11Z","timestamp":1761513371097},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,10,18]],"date-time":"2013-10-18T00:00:00Z","timestamp":1382054400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1007\/s00198-013-2518-z","type":"journal-article","created":{"date-parts":[[2013,10,17]],"date-time":"2013-10-17T06:45:17Z","timestamp":1381992317000},"page":"349-357","source":"Crossref","is-referenced-by-count":25,"title":["Long-term fracture rates seen with continued ibandronate treatment: pooled analysis of DIVA and MOBILE long-term extension studies"],"prefix":"10.1007","volume":"25","author":[{"given":"P. D.","family":"Miller","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. R.","family":"Recker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Silverman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Felsenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Reginster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B-M.","family":"Day","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Barr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Masanauskaite","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,10,18]]},"reference":[{"key":"2518_CR1","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1517\/14656566.1.2.225","volume":"1","author":"MR McClung","year":"2000","unstructured":"McClung MR (2000) Bisphosphonates in osteoporosis: recent clinical experience. Expert Opin Pharmacother 1:225\u2013238","journal-title":"Expert Opin Pharmacother"},{"key":"2518_CR2","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1001\/jama.2009.50","volume":"301","author":"D Bliuc","year":"2009","unstructured":"Bliuc D, Nguyen ND, Milch VE, Nguyen TV, Eisman JA, Center JR (2009) Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA 301:513\u2013521","journal-title":"JAMA"},{"key":"2518_CR3","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1503\/cmaj.081720","volume":"181","author":"G Ioannidis","year":"2009","unstructured":"Ioannidis G, Papaioannou A, Hopman WM, Akhtar-Danesh N, Anastassiades T, Pickard L, Kennedy CC, Prior JC, Olszynski WP, Davison KS, Goltzman D, Thabane L, Gafni A, Papadimitropoulos EA, Brown JP, Josse RG, Hanley DA, Adachi JD (2009) Relation between fractures and mortality: results from the Canadian Multicentre Osteoporosis Study. Cmaj 181:265\u2013271","journal-title":"Cmaj"},{"key":"2518_CR4","first-page":"193","volume":"79","author":"MG Sweet","year":"2009","unstructured":"Sweet MG, Sweet JM, Jeremiah MP, Galazka SS (2009) Diagnosis and treatment of osteoporosis. Am Fam Physician 79:193\u2013200","journal-title":"Am Fam Physician"},{"key":"2518_CR5","unstructured":"US Food and Drug Administration (1994) Guidelines for preclinical and clinical evaluation of agents used in the prevention or treatment of postmenopausal osteoporosis, Silver Spring"},{"key":"2518_CR6","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1359\/jbmr.081214","volume":"24","author":"S Boonen","year":"2009","unstructured":"Boonen S, Orwoll ES, Wenderoth D, Stoner KJ, Eusebio R, Delmas PD (2009) Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study. J Bone Miner Res 24:719\u2013725","journal-title":"J Bone Miner Res"},{"key":"2518_CR7","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.bone.2007.09.001","volume":"42","author":"PD Delmas","year":"2008","unstructured":"Delmas PD, McClung MR, Zanchetta JR, Racewicz A, Roux C, Benhamou CL, Man Z, Eusebio RA, Beary JF, Burgio DE, Matzkin E, Boonen S (2008) Efficacy and safety of risedronate 150\u00a0mg once a month in the treatment of postmenopausal osteoporosis. Bone 42:36\u201342","journal-title":"Bone"},{"key":"2518_CR8","first-page":"1","volume":"12","author":"T Schnitzer","year":"2000","unstructured":"Schnitzer T, Bone HG, Crepaldi G, Adami S, McClung M, Kiel D, Felsenberg D, Recker RR, Tonino RP, Roux C, Pinchera A, Foldes AJ, Greenspan SL, Levine MA, Emkey R, Santora AC 2nd, Kaur A, Thompson DE, Yates J, Orloff JJ (2000) Therapeutic equivalence of alendronate 70\u00a0mg once-weekly and alendronate 10\u00a0mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging (Milano) 12:1\u201312","journal-title":"Aging (Milano)"},{"key":"2518_CR9","doi-asserted-by":"crossref","first-page":"S212","DOI":"10.1007\/s00198-005-1975-4","volume":"17","author":"JA Eisman","year":"2006","unstructured":"Eisman JA, Garcia-Hernandez PA, Ortiz-Luna G, Ste-Marie LG, Hughes C, Mairon N, Masanauskaite D, Delmas PD (2006) Intermittent intravenous ibandronate injections are an effective treatment option in postmenopausal osteoporosis: 2-year results from DIVA [abstract P316SA]. Osteoporos Int 17:S212","journal-title":"Osteoporos Int"},{"key":"2518_CR10","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/j.amjmed.2005.12.020","volume":"119","author":"SL Bonnick","year":"2006","unstructured":"Bonnick SL, Shulman L (2006) Monitoring osteoporosis therapy: bone mineral density, bone turnover markers, or both? Am J Med 119:S25\u2013S31","journal-title":"Am J Med"},{"key":"2518_CR11","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1210\/jcem.87.4.8415","volume":"87","author":"MC Hochberg","year":"2002","unstructured":"Hochberg MC, Greenspan S, Wasnich RD, Miller P, Thompson DE, Ross PD (2002) Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 87:1586\u20131592","journal-title":"J Clin Endocrinol Metab"},{"key":"2518_CR12","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s11914-005-0018-6","volume":"3","author":"PD Miller","year":"2005","unstructured":"Miller PD (2005) Bone density and markers of bone turnover in predicting fracture risk and how changes in these measures predict fracture risk reduction. Curr Osteoporos Rep 3:103\u2013110","journal-title":"Curr Osteoporos Rep"},{"key":"2518_CR13","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/BF02938621","volume":"5","author":"PD Miller","year":"2007","unstructured":"Miller PD (2007) Monitoring osteoporosis therapies. Curr Osteoporos Rep 5:38\u201343","journal-title":"Curr Osteoporos Rep"},{"key":"2518_CR14","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1210\/jcem.84.6.5710","volume":"84","author":"PD Miller","year":"1999","unstructured":"Miller PD, Zapalowski C, Kulak CA, Bilezikian JP (1999) Bone densitometry: the best way to detect osteoporosis and to monitor therapy. J Clin Endocrinol Metab 84:1867\u20131871","journal-title":"J Clin Endocrinol Metab"},{"key":"2518_CR15","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1210\/jcem.85.1.6267","volume":"85","author":"RD Wasnich","year":"2000","unstructured":"Wasnich RD, Miller PD (2000) Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab 85:231\u2013236","journal-title":"J Clin Endocrinol Metab"},{"key":"2518_CR16","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1002\/jbmr.1673","volume":"27","author":"PD Miller","year":"2012","unstructured":"Miller PD (2012) Bone strength and surrogate markers: the first, second, and third fiddle. J Bone Miner Res 27:1623\u20131626","journal-title":"J Bone Miner Res"},{"key":"2518_CR17","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1185\/030079905X30752","volume":"21","author":"CH Chesnut","year":"2005","unstructured":"Chesnut CH, Ettinger MP, Miller PD, Baylink DJ, Emkey R, Harris ST, Wasnich RD, Watts NB, Schimmer RC, Recker RR (2005) Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONE. Curr Med Res Opin 21:391\u2013401","journal-title":"Curr Med Res Opin"},{"key":"2518_CR18","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1359\/JBMR.040325","volume":"19","author":"CH Chesnut","year":"2004","unstructured":"Chesnut CH, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A, Felsenberg D, Huss H, Gilbride J, Schimmer RC, Delmas PD (2004) Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19:1241\u20131249","journal-title":"J Bone Miner Res"},{"key":"2518_CR19","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1136\/ard.2005.044958","volume":"65","author":"JY Reginster","year":"2006","unstructured":"Reginster JY, Adami S, Lakatos P, Greenwald M, Stepan JJ, Silverman SL, Christiansen C, Rowell L, Mairon N, Bonvoisin B, Drezner MK, Emkey R, Felsenberg D, Cooper C, Delmas PD, Miller PD (2006) Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2\u00a0year results from the MOBILE study. Ann Rheum Dis 65:654\u2013661","journal-title":"Ann Rheum Dis"},{"key":"2518_CR20","first-page":"488","volume":"35","author":"JA Eisman","year":"2008","unstructured":"Eisman JA, Civitelli R, Adami S, Czerwinski E, Recknor C, Prince R, Reginster JY, Zaidi M, Felsenberg D, Hughes C, Mairon N, Masanauskaite D, Reid DM, Delmas PD, Recker RR (2008) Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study. J Rheumatol 35:488\u2013497","journal-title":"J Rheumatol"},{"key":"2518_CR21","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1185\/030079908X253717","volume":"24","author":"ST Harris","year":"2008","unstructured":"Harris ST, Blumentals WA, Miller PD (2008) Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies. Curr Med Res Opin 24:237\u2013245","journal-title":"Curr Med Res Opin"},{"key":"2518_CR22","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1359\/JBMR.050313","volume":"20","author":"PD Miller","year":"2005","unstructured":"Miller PD, McClung MR, Macovei L, Stakkestad JA, Luckey M, Bonvoisin B, Reginster JY, Recker RR, Hughes C, Lewiecki EM, Felsenberg D, Delmas PD, Kendler DL, Bolognese MA, Mairon N, Cooper C (2005) Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res 20:1315\u20131322","journal-title":"J Bone Miner Res"},{"key":"2518_CR23","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1002\/art.21918","volume":"54","author":"PD Delmas","year":"2006","unstructured":"Delmas PD, Adami S, Strugala C, Stakkestad JA, Reginster JY, Felsenberg D, Christiansen C, Civitelli R, Drezner MK, Recker RR, Bolognese M, Hughes C, Masanauskaite D, Ward P, Sambrook P, Reid DM (2006) Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis Rheum 54:1838\u20131846","journal-title":"Arthritis Rheum"},{"key":"2518_CR24","first-page":"681","volume":"66","author":"A Cranney","year":"2007","unstructured":"Cranney A, Wells G, Adachi R (2007) Non-vertebral fracture reduction with high- versus low-dose ibandronate: a meta-analysis of individual patient data. Ann Rheum Dis 66:681","journal-title":"Ann Rheum Dis"},{"key":"2518_CR25","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.bone.2009.01.002","volume":"44","author":"ST Harris","year":"2009","unstructured":"Harris ST, Reginster JY, Harley C, Blumentals WA, Poston SA, Barr CE, Silverman SL (2009) Risk of fracture in women treated with monthly oral ibandronate or weekly bisphosphonates: the eValuation of IBandronate Efficacy (VIBE) database fracture study. Bone 44:758\u2013765","journal-title":"Bone"},{"key":"2518_CR26","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s00223-010-9400-1","volume":"87","author":"SL Silverman","year":"2010","unstructured":"Silverman SL (2010) Osteoporosis therapies: evidence from health-care databases and observational population studies. Calcif Tissue Int 87:375\u2013384","journal-title":"Calcif Tissue Int"},{"key":"2518_CR27","doi-asserted-by":"crossref","first-page":"S191","DOI":"10.1007\/s00198-009-0842-0","volume":"20","author":"PD Miller","year":"2009","unstructured":"Miller PD, Recker RR, Felsenberg D, Reginster JY, Riis BJ, Czerwinski E, Lorenc RS, Stakkestad JA, Dasic G, Barr CE, Lakatos P (2009) 5-year efficacy and safety of monthly oral ibandronate: results of the MOBILE long-term extension study. Osteoporos Int 20:S191\u2013S229","journal-title":"Osteoporos Int"},{"key":"2518_CR28","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1007\/s10067-007-0824-6","volume":"27","author":"JA Stakkestad","year":"2008","unstructured":"Stakkestad JA, Lakatos P, Lorenc R, Sedarati F, Neate C, Reginster JY (2008) Monthly oral ibandronate is effective and well tolerated after 3\u00a0years: the MOBILE long-term extension. Clin Rheumatol 27:955\u2013960","journal-title":"Clin Rheumatol"},{"key":"2518_CR29","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.bone.2004.01.008","volume":"34","author":"R Recker","year":"2004","unstructured":"Recker R, Stakkestad JA, Chesnut CH 3rd, Christiansen C, Skag A, Hoiseth A, Ettinger M, Mahoney P, Schimmer RC, Delmas PD (2004) Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis. Bone 34:890\u2013899","journal-title":"Bone"},{"key":"2518_CR30","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1210\/er.2001-3002","volume":"23","author":"A Cranney","year":"2002","unstructured":"Cranney A, Tugwell P, Adachi J, Weaver B, Zytaruk N, Papaioannou A, Robinson V, Shea B, Wells G, Guyatt G (2002) Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocr Rev 23:517\u2013523","journal-title":"Endocr Rev"},{"key":"2518_CR31","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s00198-008-0653-8","volume":"20","author":"A Cranney","year":"2009","unstructured":"Cranney A, Wells GA, Yetisir E, Adami S, Cooper C, Delmas PD, Miller PD, Papapoulos S, Reginster JY, Sambrook PN, Silverman S, Siris E, Adachi JD (2009) Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data. Osteoporos Int 20:291\u2013297","journal-title":"Osteoporos Int"},{"key":"2518_CR32","unstructured":"National Osteoporosis Foundation (2008) Clinician's guide to prevention and treatment of osteoporosis. Washington, 1\u201337"},{"key":"2518_CR33","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa030897","volume":"350","author":"HG Bone","year":"2004","unstructured":"Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP, Rodriguez-Portales JA, Downs RW, Gupta J, Santora AC, Liberman UA (2004) Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350:1189\u20131199","journal-title":"N Engl J Med"},{"key":"2518_CR34","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1007\/s00198-007-0367-3","volume":"18","author":"JP Devogelaer","year":"2007","unstructured":"Devogelaer JP, Brown JP, Burckhardt P, Meunier PJ, Goemaere S, Lippuner K, Body JJ, Samsioe G, Felsenberg D, Fashola T, Sanna L, Ortmann CE, Trechsel U, Krasnow J, Eriksen EF, Garnero P (2007) Zoledronic acid efficacy and safety over five years in postmenopausal osteoporosis. Osteoporos Int 18:1211\u20131218","journal-title":"Osteoporos Int"},{"key":"2518_CR35","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1002\/jbmr.1570","volume":"27","author":"S Boonen","year":"2012","unstructured":"Boonen S, Ferrari S, Miller PD, Eriksen EF, Sambrook PN, Compston J, Reid IR, Vanderschueren D, Cosman F (2012) Postmenopausal osteoporosis treatment with antiresorptives: effects of discontinuation or long-term continuation on bone turnover and fracture risk\u2013a perspective. J Bone Miner Res 27:963\u2013974","journal-title":"J Bone Miner Res"},{"key":"2518_CR36","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1210\/jc.2012-1027","volume":"97","author":"S Khosla","year":"2012","unstructured":"Khosla S, Bilezikian JP, Dempster DW, Lewiecki EM, Miller PD, Neer RM, Recker RR, Shane E, Shoback D, Potts JT (2012) Benefits and risks of bisphosphonate therapy for osteoporosis. J Clin Endocrinol Metab 97:2272\u20132282","journal-title":"J Clin Endocrinol Metab"},{"key":"2518_CR37","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.amjmed.2012.06.023","volume":"126","author":"M McClung","year":"2013","unstructured":"McClung M, Harris ST, Miller PD, Bauer DC, Davison KS, Dian L, Hanley DA, Kendler DL, Yuen CK, Lewiecki EM (2013) Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday. Am J Med 126:13\u201320","journal-title":"Am J Med"},{"key":"2518_CR38","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1056\/NEJMp1202619","volume":"366","author":"M Whitaker","year":"2012","unstructured":"Whitaker M, Guo J, Kehoe T, Benson G (2012) Bisphosphonates for osteoporosis\u2013where do we go from here? N Engl J Med 366:2048\u20132051","journal-title":"N Engl J Med"},{"key":"2518_CR39","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s001980050010","volume":"11","author":"J Reginster","year":"2000","unstructured":"Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, Lund B, Ethgen D, Pack S, Roumagnac I, Eastell R (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 11:83\u201391","journal-title":"Osteoporos Int"},{"key":"2518_CR40","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","volume":"356","author":"DM Black","year":"2007","unstructured":"Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809\u20131822","journal-title":"N Engl J Med"},{"key":"2518_CR41","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","volume":"280","author":"SR Cummings","year":"1998","unstructured":"Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280:2077\u20132082","journal-title":"JAMA"},{"key":"2518_CR42","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM200102013440503","volume":"344","author":"MR McClung","year":"2001","unstructured":"McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier PJ, Reginster JY (2001) Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344:333\u2013340","journal-title":"N Engl J Med"},{"key":"2518_CR43","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/jbmr.1494","volume":"27","author":"DM Black","year":"2012","unstructured":"Black DM, Reid IR, Boonen S, Bucci-Rechtweg C, Cauley JA, Cosman F, Cummings SR, Hue TF, Lippuner K, Lakatos P, Leung PC, Man Z, Martinez RL, Tan M, Ruzycky ME, Su G, Eastell R (2012) The effect of 3 versus 6\u00a0years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res 27:243\u2013254","journal-title":"J Bone Miner Res"},{"key":"2518_CR44","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/S8756-3282(02)00946-8","volume":"32","author":"OH Sorensen","year":"2003","unstructured":"Sorensen OH, Crawford GM, Mulder H, Hosking DJ, Gennari C, Mellstrom D, Pack S, Wenderoth D, Cooper C, Reginster JY (2003) Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience. Bone 32:120\u2013126","journal-title":"Bone"},{"key":"2518_CR45","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","volume":"296","author":"DM Black","year":"2006","unstructured":"Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, Satterfield S, Wallace RB, Bauer DC, Palermo L, Wehren LE, Lombardi A, Santora AC, Cummings SR (2006) Effects of continuing or stopping alendronate after 5\u00a0years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 296:2927\u20132938","journal-title":"JAMA"},{"key":"2518_CR46","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1002\/jbmr.11","volume":"25","author":"AV Schwartz","year":"2010","unstructured":"Schwartz AV, Bauer DC, Cummings SR, Cauley JA, Ensrud KE, Palermo L, Wallace RB, Hochberg MC, Feldstein AC, Lombardi A, Black DM (2010) Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial. J Bone Miner Res 25:976\u2013982","journal-title":"J Bone Miner Res"},{"key":"2518_CR47","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMc080861","volume":"359","author":"EB Kwek","year":"2008","unstructured":"Kwek EB, Koh JS, Howe TS (2008) More on atypical fractures of the femoral diaphysis. N Engl J Med 359:316\u2013317, author reply 317\u2013318","journal-title":"N Engl J Med"},{"key":"2518_CR48","first-page":"317","volume":"359","author":"P Lee","year":"2008","unstructured":"Lee P, Seibel MJ (2008) More on atypical fractures of the femoral diaphysis. N Engl J Med 359:317, author reply 317\u2013318","journal-title":"N Engl J Med"},{"key":"2518_CR49","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1056\/NEJMc0707493","volume":"358","author":"BA Lenart","year":"2008","unstructured":"Lenart BA, Lorich DG, Lane JM (2008) Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med 358:1304\u20131306","journal-title":"N Engl J Med"},{"key":"2518_CR50","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1210\/jc.2004-0952","volume":"90","author":"CV Odvina","year":"2005","unstructured":"Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY (2005) Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 90:1294\u20131301","journal-title":"J Clin Endocrinol Metab"},{"key":"2518_CR51","doi-asserted-by":"crossref","first-page":"2948","DOI":"10.1210\/jc.2007-2803","volume":"93","author":"M Visekruna","year":"2008","unstructured":"Visekruna M, Wilson D, McKiernan FE (2008) Severely suppressed bone turnover and atypical skeletal fragility. J Clin Endocrinol Metab 93:2948\u20132952","journal-title":"J Clin Endocrinol Metab"},{"key":"2518_CR52","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1002\/jbmr.1719","volume":"27","author":"RM Dell","year":"2012","unstructured":"Dell RM, Adams AL, Greene DF, Funahashi TT, Silverman SL, Eisemon EO, Zhou H, Burchette RJ, Ott SM (2012) Incidence of atypical nontraumatic diaphyseal fractures of the femur. J Bone Miner Res 27:2544\u20132550","journal-title":"J Bone Miner Res"},{"key":"2518_CR53","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bone.2012.10.016","volume":"52","author":"J Schilcher","year":"2013","unstructured":"Schilcher J, Koeppen V, Ranstam J, Skripitz R, Michaelsson K, Aspenberg P (2013) Atypical femoral fractures are a separate entity, characterized by highly specific radiographic features. A comparison of 59 cases and 218 controls. Bone 52:389\u2013392","journal-title":"Bone"},{"key":"2518_CR54","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1002\/jbmr.253","volume":"25","author":"E Shane","year":"2010","unstructured":"Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA, Brown TD, Cheung AM, Cosman F, Curtis JR, Dell R, Dempster D, Einhorn TA, Genant HK, Geusens P, Klaushofer K, Koval K, Lane JM, McKiernan F, McKinney R, Ng A, Nieves J, O'Keefe R, Papapoulos S, Sen HT, van der Meulen MC, Weinstein RS, Whyte M (2010) Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 25:2267\u20132294","journal-title":"J Bone Miner Res"},{"key":"2518_CR55","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/sim.1023","volume":"21","author":"JA Berlin","year":"2002","unstructured":"Berlin JA, Santanna J, Schmid CH, Szczech LA, Feldman HI (2002) Individual patient- versus group-level data meta-regressions for the investigation of treatment effect modifiers: ecological bias rears its ugly head. Stat Med 21:371\u2013387","journal-title":"Stat Med"},{"key":"2518_CR56","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1081\/BIP-120024209","volume":"13","author":"Z Li","year":"2003","unstructured":"Li Z, Meredith MP (2003) Exploring the relationship between surrogates and clinical outcomes: analysis of individual patient data vs. meta-regression on group-level summary statistics. J Biopharm Stat 13:777\u2013792","journal-title":"J Biopharm Stat"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-013-2518-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00198-013-2518-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-013-2518-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T11:08:56Z","timestamp":1558609736000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00198-013-2518-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,18]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["2518"],"URL":"https:\/\/doi.org\/10.1007\/s00198-013-2518-z","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,18]]}}}